B. Riley Predicts Cytokinetics’ Q1 Earnings (NASDAQ:CYTK)

Cytokinetics, Incorporated (NASDAQ:CYTK) – Analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for shares of Cytokinetics in a research note issued to investors on Wednesday, March 5th. B. Riley analyst M. Mamtani expects that the biopharmaceutical company will post earnings per share of ($1.46) for the quarter. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. B. Riley also issued estimates for Cytokinetics’ Q2 2025 earnings at ($1.40) EPS, Q3 2025 earnings at ($1.44) EPS, Q4 2025 earnings at ($1.34) EPS and FY2029 earnings at $1.06 EPS.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.03. The business had revenue of $16.93 million during the quarter, compared to analysts’ expectations of $14.26 million.

CYTK has been the topic of several other research reports. Royal Bank of Canada upped their price objective on Cytokinetics from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Wednesday, December 18th. Morgan Stanley upgraded Cytokinetics from an “equal weight” rating to an “overweight” rating and lowered their price objective for the company from $70.00 to $67.00 in a research note on Thursday, February 13th. Evercore ISI raised Cytokinetics to a “strong-buy” rating in a research note on Friday, February 7th. Needham & Company LLC reiterated a “buy” rating and issued a $72.00 target price on shares of Cytokinetics in a research note on Thursday, February 6th. Finally, Stifel Nicolaus initiated coverage on shares of Cytokinetics in a research note on Wednesday, January 22nd. They set a “buy” rating and a $80.00 target price on the stock. Two analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $82.00.

Cytokinetics Price Performance

CYTK stock opened at $43.88 on Thursday. The stock has a 50-day moving average price of $47.00 and a two-hundred day moving average price of $51.03. Cytokinetics has a 12-month low of $40.53 and a 12-month high of $75.71. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.93. The company has a market cap of $5.20 billion, a PE ratio of -8.16 and a beta of 0.95.

Hedge Funds Weigh In On Cytokinetics

A number of large investors have recently bought and sold shares of CYTK. GF Fund Management CO. LTD. bought a new stake in shares of Cytokinetics during the fourth quarter valued at approximately $117,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. purchased a new stake in shares of Cytokinetics during the 4th quarter valued at about $15,483,000. Vestal Point Capital LP grew its holdings in Cytokinetics by 56.7% during the 4th quarter. Vestal Point Capital LP now owns 2,350,000 shares of the biopharmaceutical company’s stock valued at $110,544,000 after purchasing an additional 850,000 shares during the last quarter. Two Sigma Advisers LP grew its stake in Cytokinetics by 5.4% in the 4th quarter. Two Sigma Advisers LP now owns 226,400 shares of the biopharmaceutical company’s stock worth $10,650,000 after acquiring an additional 11,700 shares in the last quarter. Finally, Teza Capital Management LLC bought a new position in Cytokinetics in the 4th quarter worth about $446,000.

Insider Activity

In related news, Director Wendall Wierenga sold 742 shares of the business’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $48.61, for a total value of $36,068.62. Following the completion of the sale, the director now directly owns 24,559 shares of the company’s stock, valued at $1,193,812.99. The trade was a 2.93 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Fady Ibraham Malik sold 7,300 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $50.64, for a total value of $369,672.00. Following the completion of the transaction, the executive vice president now owns 116,071 shares in the company, valued at $5,877,835.44. The trade was a 5.92 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 17,822 shares of company stock worth $874,048. Company insiders own 3.40% of the company’s stock.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.